Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2018 2
2019 3
2020 2
2021 3
2022 1
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Benefit of Preemptive Pharmacogenetic Information on Clinical Outcome.
Roden DM, Van Driest SL, Mosley JD, Wells QS, Robinson JR, Denny JC, Peterson JF. Roden DM, et al. Clin Pharmacol Ther. 2018 May;103(5):787-794. doi: 10.1002/cpt.1035. Epub 2018 Mar 13. Clin Pharmacol Ther. 2018. PMID: 29377064 Free PMC article. Review.
The development of new knowledge around the genetic determinants of variable drug action has naturally raised the question of how this new knowledge can be used to improve the outcome of drug therapy. Two broad approaches have been taken: a point-of-care approach in …
The development of new knowledge around the genetic determinants of variable drug action has naturally raised the question of how this new k …
A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study.
Swen JJ, van der Wouden CH, Manson LE, Abdullah-Koolmees H, Blagec K, Blagus T, Böhringer S, Cambon-Thomsen A, Cecchin E, Cheung KC, Deneer VH, Dupui M, Ingelman-Sundberg M, Jonsson S, Joefield-Roka C, Just KS, Karlsson MO, Konta L, Koopmann R, Kriek M, Lehr T, Mitropoulou C, Rial-Sebbag E, Rollinson V, Roncato R, Samwald M, Schaeffeler E, Skokou M, Schwab M, Steinberger D, Stingl JC, Tremmel R, Turner RM, van Rhenen MH, Dávila Fajardo CL, Dolžan V, Patrinos GP, Pirmohamed M, Sunder-Plassmann G, Toffoli G, Guchelaar HJ; Ubiquitous Pharmacogenomics Consortium. Swen JJ, et al. Lancet. 2023 Feb 4;401(10374):347-356. doi: 10.1016/S0140-6736(22)01841-4. Lancet. 2023. PMID: 36739136 Clinical Trial.
However, the clinical utility of a pre-emptive genotyping strategy using a pharmacogenetic panel has not been rigorously assessed. ...Patients aged 18 years or older receiving a first prescription for a drug clinically recommended in the guidelines of the Dut …
However, the clinical utility of a pre-emptive genotyping strategy using a pharmacogenetic panel has not been rigorously asses …
Drug-Drug-Gene Interactions in Cardiovascular Medicine.
Asiimwe IG, Pirmohamed M. Asiimwe IG, et al. Pharmgenomics Pers Med. 2022 Nov 2;15:879-911. doi: 10.2147/PGPM.S338601. eCollection 2022. Pharmgenomics Pers Med. 2022. PMID: 36353710 Free PMC article. Review.
We provide examples of studies that have reported the prevalence of clinically relevant interactions and the most implicated cardiovascular medicines before outlining the challenges associated with dealing with these interactions in clinical practice. Finally, we pr …
We provide examples of studies that have reported the prevalence of clinically relevant interactions and the most implicated cardiova …
Preemptive pharmacogenetic testing: exploring the knowledge and perspectives of US payers.
Keeling NJ, Rosenthal MM, West-Strum D, Patel AS, Haidar CE, Hoffman JM. Keeling NJ, et al. Genet Med. 2019 May;21(5):1224-1232. doi: 10.1038/gim.2017.181. Epub 2017 Oct 26. Genet Med. 2019. PMID: 31048813 Free PMC article.
PURPOSE: Preemptive pharmacogenetic testing aims to optimize medication use by having genetic information at the point of prescribing. ...Three concept domains and ten dimensions were developed. Key findings include clinical utility concerns and limite …
PURPOSE: Preemptive pharmacogenetic testing aims to optimize medication use by having genetic information at the point …
Global Frequencies of Clinically Important HLA Alleles and Their Implications For the Cost-Effectiveness of Preemptive Pharmacogenetic Testing.
Zhou Y, Krebs K, Milani L, Lauschke VM. Zhou Y, et al. Clin Pharmacol Ther. 2021 Jan;109(1):160-174. doi: 10.1002/cpt.1944. Epub 2020 Jul 26. Clin Pharmacol Ther. 2021. PMID: 32535895
Human leukocyte antigen (HLA)-B*57:01, HLA-B*15:02, HLA-A*31:01, and HLA-B*58:01 constitute established risk factors and preemptive genotyping of these HLA alleles in patients prior to the initiation of abacavir, carbamazepine, and allopurinol-based therapies can prevent t …
Human leukocyte antigen (HLA)-B*57:01, HLA-B*15:02, HLA-A*31:01, and HLA-B*58:01 constitute established risk factors and preemptive g …
Precision medicine in cardiovascular therapeutics: Evaluating the role of pharmacogenetic analysis prior to drug treatment.
Ingelman-Sundberg M, Pirmohamed M. Ingelman-Sundberg M, et al. J Intern Med. 2024 May;295(5):583-598. doi: 10.1111/joim.13772. Epub 2024 Feb 11. J Intern Med. 2024. PMID: 38343077 Review.
In this review, we critically assess the clinical application of pharmacogenomics in cardiovascular disease and delineate present and future utilization of pharmacogenomics. ...In summary, we contend that cardiovascular pharmacogenomic analyses are underpinned by a wealth …
In this review, we critically assess the clinical application of pharmacogenomics in cardiovascular disease and delineate present and …
Assessment of the Implementation of Pharmacogenomic Testing in a Pediatric Tertiary Care Setting.
Cohn I, Manshaei R, Liston E, Okello JBA, Khan R, Curtis MR, Krupski AJ, Jobling RK, Kalbfleisch K, Paton TA, Reuter MS, Hayeems RZ, Verstegen RHJ, Goldman A, Kim RH, Ito S. Cohn I, et al. JAMA Netw Open. 2021 May 3;4(5):e2110446. doi: 10.1001/jamanetworkopen.2021.10446. JAMA Netw Open. 2021. PMID: 34037732 Free PMC article.
OBJECTIVES: To assess the implementation outcomes of a PGx testing program comprising both a point-of-care model that examined targeted drugs and a preemptive model informed by whole-genome sequencing that evaluated a broad range of drugs for potential …
OBJECTIVES: To assess the implementation outcomes of a PGx testing program comprising both a point-of-care model that examined …
CYP2D6 Genotype-guided Metoprolol Therapy in Cardiac Surgery Patients: Rationale and Design of the Pharmacogenetic-guided Metoprolol Management for Postoperative Atrial Fibrillation in Cardiac Surgery (PREEMPTIVE) Pilot Study.
Dunham WC, Weinger MB, Slagle J, Pretorius M, Shah AS, Absi TS, Shotwell MS, Beller M, Thomas E, Vnencak-Jones CL, Freundlich RE, Wanderer JP, Sandberg WS, Kertai MD. Dunham WC, et al. J Cardiothorac Vasc Anesth. 2020 Jan;34(1):20-28. doi: 10.1053/j.jvca.2019.09.003. Epub 2019 Sep 10. J Cardiothorac Vasc Anesth. 2020. PMID: 31606278 Free PMC article.
OBJECTIVES: The Preemptive Pharmacogenetic-guided Metoprolol Management for Atrial Fibrillation in Cardiac Surgery (PREEMPTIVE) pilot trial aims to use existing institutional resources to develop a process for integrating CYP2D6 pharmacogenetic test re …
OBJECTIVES: The Preemptive Pharmacogenetic-guided Metoprolol Management for Atrial Fibrillation in Cardiac Surgery (PREEMPT …
A Cost-Consequence Analysis of Preemptive SLCO1B1 Testing for Statin Myopathy Risk Compared to Usual Care.
Brunette CA, Dong OM, Vassy JL, Danowski ME, Alexander N, Antwi AA, Christensen KD. Brunette CA, et al. J Pers Med. 2021 Oct 31;11(11):1123. doi: 10.3390/jpm11111123. J Pers Med. 2021. PMID: 34834475 Free PMC article.
Despite its potential clinical application, the cost implications of SLCO1B1 testing are largely unknown. We conducted a cost-consequence analysis of preemptive SLCO1B1 testing (PGx+) versus usual care (PGx-) among Veteran patients enrolled in the Integrating …
Despite its potential clinical application, the cost implications of SLCO1B1 testing are largely unknown. We conducted a cost-consequ …
The Integrating Pharmacogenetics in Clinical Care (I-PICC) Study: Protocol for a point-of-care randomized controlled trial of statin pharmacogenetics in primary care.
Vassy JL, Brunette CA, Majahalme N, Advani S, MacMullen L, Hau C, Zimolzak AJ, Miller SJ. Vassy JL, et al. Contemp Clin Trials. 2018 Dec;75:40-50. doi: 10.1016/j.cct.2018.10.010. Epub 2018 Oct 24. Contemp Clin Trials. 2018. PMID: 30367991 Free PMC article.
The primary outcome is the change in low-density lipoprotein cholesterol (LDL-C) after one year. Secondary outcomes are concordance with Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for simvastatin prescribing, concordance with …
The primary outcome is the change in low-density lipoprotein cholesterol (LDL-C) after one year. Secondary outcomes are concor …
11 results